On the other hand, FoxO1's ‘oncogenic’ character has been described in Burkitt lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia, with malignant B cells utilizing FoxO1 to increase their fitness [8, 9, 10]. This evidence concerns the gene FOXO1 and mantle cell lymphoma.